Acyclovir Ophthalmic

Acyclovir Ophthalmic is filed as Ophthalmic Antiviral. The sections below restate public label fields stored for this profile.

Class
Ophthalmic Antiviral
Route
ORAL
Dosage forms
3 DOSAGE FORMS AND STRENGTHS AVACLYR is an ophthalmic ointment containing 3% acyclovir. Ophthalmic ointment containing 3% acyclovir.
Generic available
Yes
Manufacturer
Fera Pharmaceuticals

Approved uses

1 INDICATIONS AND USAGE AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus. AVACLYR (acyclovir ophthalmic ointment) 3%, a herpes simplex virus nucleoside analog DNA polymerase inhibitor, is indicated in the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.

How it works

12.1 Mechanism of Action Acyclovir is an antiviral drug [see Microbiology ( 12.4 )] .

Warnings and precautions

5 WARNINGS AND PRECAUTIONS AVACLYR is indicated for topical ophthalmic use. ( 5.1 ) Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with AVACLYR. ( 5.2 ) 5.1 Topical Ophthalmic Use AVACLYR is indicated for topical ophthalmic use. 5.2 Avoidance of Contact Lenses Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with AVACLYR. 5.3 Risk of Contamination This product is sterile when packaged. Patients should be advised to not allow the tip of the container to touch any surface, as this may contaminate the ointment. If pain develops, or if redness, itching, or inflammation becomes aggravated, the patient should be advised to consult a physician.

Contraindications

4 CONTRAINDICATIONS AVACLYR is contraindicated for patients who develop sensitivity to acyclovir or valacyclovir. AVACLYR is contraindicated in patients with a known hypersensitivity to acyclovir or valacyclovir.

Common side effects

Eye pain (2-10%); Punctate keratitis (2-10%); Follicular conjunctivitis (2-10%)

Adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions (2-10%) reported in patients were eye pain (stinging), punctate keratitis and follicular conjunctivitis. Rare reports of blepharitis and very rare reports of immediate hypersensitivity reactions including angioedema and urticaria have been observed post-marketing in patients taking AVACLYR. The most common adverse reactions (2 to 10%) reported in patients were eye pain (stinging), punctate keratitis and follicular conjunctivitis. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Fera Pharmaceuticals, LLC at (414) 434-6604 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Dosage and administration

2 DOSAGE AND ADMINISTRATION The recommended dosing regimen is to apply a 1 cm ribbon of ointment in the lower cul-de-sac of the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals and then a 1 cm ribbon 3 times per day for 7 days. Apply a 1 cm ribbon in the lower cul-de-sac of the affected eye 5 times per day until healed then 3 times per day for 7 days. ( 2 )

Drug interactions

7 DRUG INTERACTIONS No clinically significant interactions have been identified resulting from topical administration of other drugs concomitantly with AVACLYR.

Patient counseling

17 PATIENT COUNSELING INFORMATION Administration Advise patients to wash hands well and pull down lower lid of the affected eye to form a pocket. Instruct the patient to apply a 1 cm (1/2 inch) ribbon of ointment in the pocket formed by the lower lid 5 times per day (approximately every 3 hours while awake). After application of the ointment, the patient should be advised to close their eye for 1-2 minutes. Excess ointment can be wiped away. Continue this dosing 5 times per day until the patient is advised by their physician that the corneal ulcer is healed. Once healed, instruct the patient to continue use of a 1 cm (1/2 inch) ribbon of ointment 3 times per day for 7 more days. [see Dosage and Administration ( 2 )]. Risk of Contamination This product is sterile when packaged. Advise patients to not allow the tip of the container to touch any surface, as this may contaminate the ointment. When to Consult a Physician Advise patients to consult a physician if pain develops, or if redness, itching, or inflammation becomes aggravated. Avoidance of Contact Lenses Advise patients to not wear contact lenses when using AVACLYR. Manufactured in Canada for: Fera Pharmaceuticals, LLC Locust Valley, N.Y. 11560 PF028 P-622V1

Common questions

What is Acyclovir Ophthalmic approved to treat?

According to its FDA label, Acyclovir Ophthalmic is approved for: 1 INDICATIONS AND USAGE AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus. AVACLYR (acyclovir ophthalmic ointment) 3%, a herpes simplex virus nucleoside analog… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Acyclovir Ophthalmic?

Acyclovir Ophthalmic belongs to the Ophthalmic Antiviral class of medications.

What form does Acyclovir Ophthalmic come in?

The FDA label lists Acyclovir Ophthalmic as: 3 DOSAGE FORMS AND STRENGTHS AVACLYR is an ophthalmic ointment containing 3% acyclovir. Ophthalmic ointment containing 3% acyclovir.; oral route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Acyclovir Ophthalmic?

Yes. A generic version of Acyclovir Ophthalmic is available in the U.S. Ask your pharmacist about substitution.

Does Acyclovir Ophthalmic have a Boxed Warning?

Our ingest of the FDA label for Acyclovir Ophthalmic does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Acyclovir Ophthalmic cost?

Public CMS NADAC pricing for Acyclovir Ophthalmic is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Acyclovir Ophthalmic currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Acyclovir Ophthalmic in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Acyclovir Ophthalmic approved by the FDA?

The FDA record lists the approval date for Acyclovir Ophthalmic as 2019-03-29.

Who makes Acyclovir Ophthalmic?

The FDA label lists Fera Pharmaceuticals as a labeler/manufacturer of Acyclovir Ophthalmic. Multiple firms may market generics of the same molecule.

How should Acyclovir Ophthalmic be stored?

The FDA label states: "Store at 15°C to 25°C (59°F to 77°F)." Follow the packaging insert for the authoritative guidance.

What is the pregnancy category for Acyclovir Ophthalmic?

The FDA label lists a pregnancy category of B for Acyclovir Ophthalmic. Pregnancy and lactation decisions should be made with a clinician.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…